drugset / Trial / NCT04752813
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2026-08-25
- Completion
- 2030-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coenzyme Q10 | Other / unclassified | 66 mg/kg | — |
| Subject | Coenzyme Q10 | Other / unclassified | 110 mg/kg | — |
| Background | Temozolomide | Small molecule | 75 mg/m2 | — |